ENT Disorder Treatment Market Expected to Reach $4.5 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “ENT Disorder Treatment Market," The ENT Disorder Treatment Market size was valued at $2.4 billion in 2021, and is estimated to reach $4.5 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031.

ENT disorders are the disorders of nose, ear and throat which consist of wide range of disease conditions that can affect these connected parts of the body. The ears allow a person to hear, and the inner ear helps stabilize the body and provide a sense of balance. The nose allows a person to smell and also assists with taste. The throat provides a way for air to reach the lungs and voice box. It also connects the mouth to the esophagus, through which food travels to reach the digestive system. The ENT disorders are mainly caused by bacterial and viral infections.  

The key factors that drive theENT Disorder Treatment Market growth are rapid changes in environmental conditions, an increase in the level of air and noise pollution, and a rise in the geriatric population. For instance, according to the report published by the technical group on population projections for India, about 138 million people are aged above 60 in India in 2021 and this is further expected to increase in 2031. Thus, the increase in the geriatric population has increased the demand for ear drops and antibiotics to treat nasal, ear, and throat infections, which drives the growth of the market.

.Moreover, the rise in the prevalence of diseases like sinusitis and chronic rhinitis across the world further drives the growth of the market. In addition, the rise in healthcare expenditure and the increase in government initiatives in developing countries are the ENT Disorder Treatment Market trends that further boost the market growth.

However, the high cost of medical devices and of surgeries for sinusitis and tonsillitis hampers the market's growth. Conversely, the emerging healthcare market in developing countries is expected to provide a lucrative opportunity for the growth of the market during the forecast period.

The ENT Industry is segmented on the basis of drug type, organ, end user and region. By drug type it is segmented into antibiotics, anti-inflammatory and others. By organ, it is segmented into ear, nose and throat. By end user the market is segmented into hospitals and clinics, homecare settings and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By drug type, the ENT disorder treatment market is segmented into antibiotics, anti-inflammatory and others. The antibiotics segment accounted for the largest share of the market. The dominance of this segment can be attributed to rise the prevalence of sinusitis, and chronic rhinitis infection across the world.

The anti-inflammatory segment is anticipated to grow at a significant rate during the forecast period owing to the rise in the geriatric population and increase in prevalence of acute and chronic infectious diseases which increase the demand for anti-inflammatory drugs across the world.

By organ, the ENT disorder treatment market is segmented into ear, nose and throat. The nose segment was the highest revenue contributor to the market, owing to the rise in the prevalence of allergic rhinitis and increase in the prevalence of viral infection across the world.

The throat segment is expected to grow at a considerable growth rate during the ENT disorder treatment market forecast period owing to increase in number of patient suffering from chronic tonsillitis across the world.

By end user, the market is categorized into hospitals and clinics, homecare settings and others. The hospitals and clinics segment was the highest revenue contributor to the market owing to the increase in the prevalence of infectious and allergic disorders such as sinusitis, tonsilitis, ear infection, nasal airway obstruction and various others.

The homecare settings segment is expected to grow at a considerable growth rate during the ENT disorder treatment market during the forecast period owing to increase in geriatric population suffering from ENT disorder.

Region-wise, the ENT disorder treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a majority of the ENT disorder treatment market share in 2021 and is anticipated to remain dominant during the forecast period owing to surge in number of private hospitals and rise in the incidence of otitis median and sinusitis infection across the region.

Asia-Pacific is anticipated to witness lucrative growth, owing to the rise in population in emerging countries like China, India, and Japan, surge in pollution, and the increase in prevalence of infectious and allergic conditions.

The key players that operate in the ENT disorder treatment market are Sanofi, Novartis, GSK, Pfizer, Vitaris, Sun Pharma, AstraZeneca, Cipla, AurbindoPharma, Teva Pharmaceuticals, Bayer AG, Amneal Pharmaceuticals Ltd, M.M Pharma, Lyra Therapeutics, Lannet Company Inc.

Key findings of the study

• By drug type, the antibiotics segment was the highest contributor to the market in 2021.
• By organ, the nose segment was the highest contributor in 2021.
• By end user, the hospitals and clinics dominated the market in 2021 and is expected to continue this trend during the forecast period.
• By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.